Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

BMRA US Equity

Biomerica IncHealth Care · In Vitro & In Vivo Diagnostic Substances · CIK 73290 · FY ends May 31
$1.52
-0.08 (-5.00%)
USD · as of 2026-08-19 · marketstack
3 registered studies · 0 active

Studies where BMRA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional · 2 observational

Held by 1 tracked-famous manager (JANE STREET GROUP, LLC) · FINRA short interest 3.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Endpoint Determination Study ProtocolNCT03459482Change in the IBS-API - Abdominal Pain Intensity. The IBS-API is being assessed daily from enrollment (baseline) to study completion; total 10 weeksRandomized · Triple-masked · TreatmentNot applicableCompletedOther: Food Elimination DietIrritable Bowel Syndrome5562021-12-31actual2024-08-05
Specimen Collection Study ProtocolNCT04468386observationalMatrix EquivalencyCompletedFocus in on Collecting Paired Specimens for Matrix Equivalency472021-05-30actual2021-11-24
Specimen Collection Study for H. Pylori TestingNCT02970110observationalNon-invasive collection procedureCompletedHelicobacter Infections982020-03-01actual2022-03-18

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19